Header Logo

Connection

MICHAEL ITTMANN to Xenograft Model Antitumor Assays

Back to Details
This is a "connection" page, showing publications MICHAEL ITTMANN has written about Xenograft Model Antitumor Assays.
MICHAEL ITTMANN
Connection Strength
0.395
Xenograft Model Antitumor Assays
  1. Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer. Prostate. 2020 01; 80(1):65-73.
    View in: PubMed
    Score: 0.125
  2. RET Signaling in Prostate Cancer. Clin Cancer Res. 2017 Aug 15; 23(16):4885-4896.
    View in: PubMed
    Score: 0.106
  3. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors. Oncotarget. 2017 Jan 24; 8(4):6179-6192.
    View in: PubMed
    Score: 0.104
  4. CKB inhibits epithelial-mesenchymal transition and prostate cancer progression by sequestering and inhibiting AKT activation. Neoplasia. 2021 11; 23(11):1147-1165.
    View in: PubMed
    Score: 0.036
  5. Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties. Oncogene. 2016 11 17; 35(46):5963-5976.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.